Class information for:
Level 1: BEDAQUILINE//INFECT DIS PHARMACOKINET//DELAMANID

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
5434 1624 39.9 73%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
141 3       TUBERCULOSIS//INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE//MYCOBACTERIUM TUBERCULOSIS 64640
2486 2             PYRAZINAMIDE//ISONIAZID//RIFAMPICIN 3933
5434 1                   BEDAQUILINE//INFECT DIS PHARMACOKINET//DELAMANID 1624

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BEDAQUILINE authKW 451676 2% 78% 31
2 INFECT DIS PHARMACOKINET address 386279 2% 62% 33
3 DELAMANID authKW 382520 1% 88% 23
4 INFECT DIS EXPT THER EUT address 360482 1% 91% 21
5 PA 824 authKW 349978 1% 85% 22
6 RIFAPENTINE authKW 331904 2% 55% 32
7 DIARYLQUINOLINE authKW 258729 1% 81% 17
8 TB address 248854 10% 8% 161
9 EARLY BACTERICIDAL ACTIVITY authKW 248831 1% 88% 15
10 TMC207 authKW 186896 1% 76% 13

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Microbiology 13140 38% 0% 614
2 Pharmacology & Pharmacy 8012 42% 0% 674
3 Infectious Diseases 6672 20% 0% 317
4 Respiratory System 6438 17% 0% 272
5 Chemistry, Medicinal 4496 16% 0% 261
6 Critical Care Medicine 654 4% 0% 69
7 Immunology 445 10% 0% 157
8 Chemistry, Organic 129 6% 0% 93
9 Medicine, General & Internal 78 5% 0% 81
10 Medical Laboratory Technology 26 1% 0% 15

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INFECT DIS PHARMACOKINET 386279 2% 62% 33
2 INFECT DIS EXPT THER EUT 360482 1% 91% 21
3 TB 248854 10% 8% 161
4 TIBOTEC BVBA 144617 1% 77% 10
5 TB SECT 109318 2% 15% 40
6 IMED INFECT 92120 0% 70% 7
7 INFECT INFLAMMAT IMAGING 60903 1% 36% 9
8 CRIT PATH TB DRUG REGIMENS 56403 0% 100% 3
9 TIBOTEC NV 56403 0% 100% 3
10 N AMER PHARMACOKINET 52220 0% 56% 5

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 64280 17% 1% 284
2 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 30809 5% 2% 84
3 TUBERCULOSIS 28318 3% 4% 43
4 ACS INFECTIOUS DISEASES 7190 0% 5% 8
5 TUBERCLE 7004 1% 3% 13
6 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 6477 4% 1% 66
7 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 5191 3% 1% 52
8 ACS MEDICINAL CHEMISTRY LETTERS 3476 1% 1% 16
9 CLINICAL INFECTIOUS DISEASES 3168 3% 0% 47
10 FUTURE MEDICINAL CHEMISTRY 2473 1% 1% 11

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 BEDAQUILINE 451676 2% 78% 31 Search BEDAQUILINE Search BEDAQUILINE
2 DELAMANID 382520 1% 88% 23 Search DELAMANID Search DELAMANID
3 PA 824 349978 1% 85% 22 Search PA+824 Search PA+824
4 RIFAPENTINE 331904 2% 55% 32 Search RIFAPENTINE Search RIFAPENTINE
5 DIARYLQUINOLINE 258729 1% 81% 17 Search DIARYLQUINOLINE Search DIARYLQUINOLINE
6 EARLY BACTERICIDAL ACTIVITY 248831 1% 88% 15 Search EARLY+BACTERICIDAL+ACTIVITY Search EARLY+BACTERICIDAL+ACTIVITY
7 TMC207 186896 1% 76% 13 Search TMC207 Search TMC207
8 R207910 169208 1% 100% 9 Search R207910 Search R207910
9 TUBERCULOSIS 151464 22% 2% 359 Search TUBERCULOSIS Search TUBERCULOSIS
10 SQ109 150399 1% 67% 12 Search SQ109 Search SQ109

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 VAN DEN BOOGAARD, J , KIBIKI, GS , KISANGA, ER , BOEREE, MJ , AARNOUTSE, RE , (2009) NEW DRUGS AGAINST TUBERCULOSIS: PROBLEMS, PROGRESS, AND EVALUATION OF AGENTS IN CLINICAL DEVELOPMENT.ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. VOL. 53. ISSUE 3. P. 849 -862 94 64% 81
2 GROSSET, JH , SINGER, TG , BISHAI, WR , (2012) NEW DRUGS FOR THE TREATMENT OF TUBERCULOSIS: HOPE AND REALITY.INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. VOL. 16. ISSUE 8. P. 1005 -1014 68 77% 54
3 ALSULTAN, A , PELOQUIN, CA , (2014) THERAPEUTIC DRUG MONITORING IN THE TREATMENT OF TUBERCULOSIS: AN UPDATE.DRUGS. VOL. 74. ISSUE 8. P. 839 -854 81 57% 39
4 GOUTELLE, S , BOURGUIGNON, L , MAIRE, P , JELLIFFE, RW , NEELY, MN , (2014) THE CASE FOR USING HIGHER DOSES OF FIRST LINE ANTI-TUBERCULOSIS DRUGS TO OPTIMIZE EFFICACY.CURRENT PHARMACEUTICAL DESIGN. VOL. 20. ISSUE 39. P. 6191 -6206 85 69% 1
5 VERBEECK, RK , GUNTHER, G , KIBUULE, D , HUNTER, C , RENNIE, TW , (2016) OPTIMIZING TREATMENT OUTCOME OF FIRST-LINE ANTI-TUBERCULOSIS DRUGS: THE ROLE OF THERAPEUTIC DRUG MONITORING.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 72. ISSUE 8. P. 905 -916 81 70% 0
6 POCE, G , COCOZZA, M , CONSALVI, S , BIAVA, M , (2014) SAR ANALYSIS OF NEW ANTI-TB DRUGS CURRENTLY IN PRE-CLINICAL AND CLINICAL DEVELOPMENT.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. VOL. 86. ISSUE . P. 335 -351 80 67% 9
7 ZUMLA, A , NAHID, P , COLE, ST , (2013) ADVANCES IN THE DEVELOPMENT OF NEW TUBERCULOSIS DRUGS AND TREATMENT REGIMENS.NATURE REVIEWS DRUG DISCOVERY. VOL. 12. ISSUE 5. P. 388 -404 51 52% 255
8 VILLEMAGNE, B , CRAUSTE, C , FLIPO, M , BAULARD, AR , DEPREZ, B , WILLAND, N , (2012) TUBERCULOSIS: THE DRUG DEVELOPMENT PIPELINE AT A GLANCE.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. VOL. 51. ISSUE . P. 1 -16 68 61% 80
9 KUMAR, D , NEGI, B , RAWAT, DS , (2015) THE ANTI-TUBERCULOSIS AGENTS UNDER DEVELOPMENT AND THE CHALLENGES AHEAD.FUTURE MEDICINAL CHEMISTRY. VOL. 7. ISSUE 15. P. 1981 -2003 80 63% 1
10 VEZIRIS, N , (2013) NEW ANTITUBERCULOUS DRUGS (2): NEW MOLECULES.JOURNAL DES ANTI-INFECTIEUX. VOL. 15. ISSUE 3. P. 133 -140 56 95% 0

Classes with closest relation at Level 1


Rank Class id link
1 20105 PYRAZINAMIDE//PNCA//PYRAZINAMIDASE
2 29696 LRMA//EQUIPE 12//L D TRANSPEPTIDASE
3 16318 ISONIAZID//RIFAMPICIN//PYRAZINAMIDE
4 567 MULTIDRUG RESISTANT TUBERCULOSIS//MDR TB//INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
5 33978 AGROCHEMICAL INTERACTIONS//ATENOLOL METABOLIC ACTIONS//METOPROLOL METABOLIC ACTIONS
6 5819 MYCOBACTERIUM AVIUM//RIFABUTIN//MYCOBACTERIUM AVIUM COMPLEX
7 29007 MICELLE FORMING POLYMER//N 2 HYDROXY 3 TRIMETHYLAMMONIUM PROPYL CHITOSAN CHLORIDE HTCC//INFECT DIS ANIM MODELS GRP
8 2106 MYCOBACTERIUM TUBERCULOSIS//PE_PGRS//TUBERCULOSIS
9 25497 AZORELLA COMPACTA//MULINANE//AZORELLANE
10 30310 GLYCOSYL AMINO ALCOHOLS//N ALKYL DIAMINE//CINNAMIC HYDRAZIDE

Go to start page